Literature DB >> 8286712

L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats.

A A Reyes1, I E Karl, J Kissane, S Klahr.   

Abstract

The effect(s) of L-arginine administration on the renal function of rats with untreated diabetes mellitus was examined. Rats received streptozotocin (N = 11) or vehicle (N = 12): Group 1 (normal rats, N = 6) drank tap water; Group 2 (normal rats, N = 6) drank tap water containing 1% L-arginine; Group 3 (diabetic rats, N = 5) drank tap water; and Group 4 (diabetic rats, N = 6) drank tap water with 1% L-arginine. Rats were fed a standard rat chow diet (22.8% protein, 142% L-arginine) with free access to food and water for 14 wk. Diabetic rats gained less weight, had significantly lower plasma levels of albumin and L-arginine, and had greater values for 24-h urine volumes and urine excretion of glucose, protein, urea, creatinine, nitrate, and nitrite than control rats. Diabetic rats given L-arginine (Group 4) had significantly lower protein and cGMP excretion in the urine than did rats of Group 3. The administration of L-arginine did not affect the plasma levels of glucose or L-arginine in Groups 2 or 4 compared with those of their respective controls. Group 3 had significantly higher values for GFR than did the other three groups of rats, but values for effective RPF, mean arterial pressure, hematocrit, and renal vascular resistance were not significantly different between Groups 3 and 4. There was no significant difference in glomerular morphology among the four groups of rats as determined by light microscopy, and both groups of diabetic rats exhibited the Armanni-Ebstein lesion in their tubules.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8286712     DOI: 10.1681/ASN.V441039

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  Circulatory and renal consequences of pregnancy in diabetic NOD mice.

Authors:  S D Burke; V F Barrette; S David; E V Khankin; M A Adams; B A Croy
Journal:  Placenta       Date:  2011-10-19       Impact factor: 3.481

2.  Nitric oxide in ischaemic acute renal failure of streptozotocin diabetic rats.

Authors:  Y Goor; G Peer; A Iaina; M Blum; Y Wollman; T Chernihovsky; D Silverberg; S Cabili
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

3.  Effects of early insulin treatment on ultrastructural changes of glomeruli in diabetic rats revealed by the quick-freezing and deep-etching method.

Authors:  T Moriya; S Ohno; K Tanaka; Y Fujii; Y Yajima
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

4.  Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.

Authors:  Yoshihiro Kuno; Masayuki Iyoda; Takanori Shibata; Yuki Hirai; Tadao Akizawa
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 5.  Pathogenic role of nitric oxide alterations in diabetic nephropathy.

Authors:  Sharma S Prabhakar
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

6.  Plasma from ESRD patients inhibits nitric oxide synthase activity in cultured human and bovine endothelial cells.

Authors:  S Xiao; R J Schmidt; C Baylis
Journal:  Acta Physiol Scand       Date:  2000-01

7.  Reactive oxygen species mediate compensatory glomerular hypertrophy in rat uninephrectomized kidney.

Authors:  Masahito Ozeki; Hajime Nagasu; Minoru Satoh; Tamehachi Namikoshi; Yoshisuke Haruna; Naruya Tomita; Tamaki Sasaki; Naoki Kashihara
Journal:  J Physiol Sci       Date:  2009-07-11       Impact factor: 2.781

Review 8.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

Review 9.  The kallikrein-kinin system in diabetic nephropathy.

Authors:  Hirofumi Tomita; Ryan B Sanford; Oliver Smithies; Masao Kakoki
Journal:  Kidney Int       Date:  2012-02-08       Impact factor: 10.612

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.